People with allergic fungal rhinosinusitis taking Dupixent saw significant improvement in congestion and sinus inflammation, ...
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results